Celsion's Vaccine Platform Shows Potential Against COVID-19 In Preclinical Studies

Celsion Corporation CLSN has announced results from preclinical in vivo studies of its next-generation PLACCINE DNA vaccine platform.
Data showed that the vaccine candidate produced antibodies and cytotoxic T-cell response specific to the spike antigen of SARS-CoV-2 in animal models.
The antibodies to the SARS-CoV-2 spike antigen prevented the infection of cultured cells in a viral neutralization assay.
The production of antibodies predicts the ability of PLACCINE to protect against SARS-CoV-2 exposure, and the elicitation of cytotoxic T-cell response shows the vaccine's potential to eradicate cells infected with SARS-CoV-2.
Celsion expects to report these data at the International Vaccines Conference to be held in October.
The Company plans to file an Investigational New Drug application with the FDA by early 2022.
Price Action: CLSN stock is up 2.91% at $1.06 during the market session on the last check Thursday.